{"entity":{"id":"nct05318573","kind":"trial","name":"A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Fujifilm Pharmaceuticals U.S.A., Inc., active and no longer recruiting.","summary":"A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT05318573 by Fujifilm Pharmaceuticals U.S.A., Inc., with 120 participants planned, started 2022-06-01 and due to reach its primary completion in 2029-05. Interventions recorded: Pembrolizumab, FF-10832. Conditions listed: Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05318573","url":"https://clinicaltrials.gov/study/NCT05318573"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05318573","phase":"2","setting":"A Phase 2a Study With Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Tumors","sponsor":"Fujifilm Pharmaceuticals U.S.A., Inc.","enrolled":120,"outcomes":[]},"route":"/trials/nct05318573/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}